Rodman & Renshaw Reiterates Enzo Biochem Market Outperform, $7 PT

Rodman & Renshaw reiterated its Enzo Biochem ENZ Market Outperform and $7 price target in a research report published today. In the report, Rodman & Renshaw states, "In keeping with our thesis, we believe there exists potential for additional novel diagnostic tests such as ColonSentry and HPV OncoTect to be in-licensed in 2011 and 2012. Enzo has the potential to generate value for the long-term investor interested in a fundamental revenue story." Shares of Enzo Biochem were trading at $3.71 at the time of posting, reflecting no change from Thursday's market close.